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Abstract
Background: Antibodies have an essential role in the acquired immune response against blood stage P. falciparum
infection. Although several antigens have been identified as important antibody targets, it is still elusive which
antigens have to be recognized for clinical protection. Herein, we analyzed antibodies from plasmas from
symptomatic or asymptomatic individuals living in the same geographic area in the Western Amazon, measuring
their recognition of multiple merozoite antigens.
Methods: Specific fragments of genes encoding merozoite proteins AMA1 and members of MSP and EBL families
from circulating P. falciparum field isolates present in asymptomatic and symptomatic patients were amplified by
PCR. After cloning and expression of different versions of the antigens as recombinant GST-fusion peptides, we
tested the reactivity of patients’ plasmas by ELISA and the presence of IgG subclasses in the most reactive plasmas.
Results: 11 out of 24 recombinant antigens were recognized by plasmas from either symptomatic or asymptomatic
infections. Antibodies to MSP9 (X2DF=1 = 9.26/p = 0.0047) and MSP5 (X
2
DF=1 = 8.29/p = 0.0069) were more prevalent in
asymptomatic individuals whereas the opposite was observed for MSP1 block 2-MAD20 (X2DF=1 = 6.41/p = 0.0206,
Fisher’s exact test). Plasmas from asymptomatic individuals reacted more intensely against MSP4 (U = 210.5, p < 0.03),
MSP5 (U = 212, p < 0.004), MSP9 (U = 189.5, p < 0.002) and EBA175 (U = 197, p < 0.014, Mann-Whitney’s U test). IgG1
and IgG3 were predominant for all antigens, but some patients also presented with IgG2 and IgG4. The recognition of
MSP5 (OR = 0.112, IC95% = 0.021-0.585) and MSP9 (OR = 0.125, IC95% = 0.030-0.529, cross tab analysis) predicted 8.9 and
8 times less chances, respectively, to present symptoms. Higher antibody levels against MSP5 and EBA175 were
associated by odds ratios of 9.4 (IC95% = 1.29-69.25) and 5.7 (IC95% = 1.12-29.62, logistic regression), respectively, with
an asymptomatic status.
Conclusions: Merozoite antigens were targets of cytophilic antibodies and antibodies against MSP5, MSP9 and EBA175
were independently associated with decreased symptoms.
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Background
Malaria along with HIV/AIDS and Tuberculosis is one of
the major causes of mortality and morbidity in tropical
areas and consequently the primary obstacle to social and
economic improvement for developing countries in these
regions [1]. Despite recent efforts to control infections
based on the use of insecticide-treated bed nets alone
or combined with indoor residual spraying [2] and
artemisinin-combined treatment [3], almost 300 million
cases and 800,000 deaths are annually registered [1,3].
Most of these deaths occur in Sub-Saharan Africa in chil-
dren under 5 years and pregnant women as a consequence
of P. falciparum infection [3]. Given the looming resist-
ance of the parasite against the derivatives of artemisinin,
concentrated and continuous efforts are necessary to con-
tain the disease. These include the facilitated access to ef-
fective treatment, the introduction of novel drugs and also
the development of efficient vaccines.
Important success has been achieved in the develop-
ment of vaccines based on pre-erythrocytic targets using
the circumsporozoite protein [4] or liver stage targets
employing knockout parasite lines [5]. The finding that
the passive transfer of immunoglobulins led to the sup-
pression of parasite multiplication and temporary cure
[6] supports the view that relevant targets are also found
on blood stage parasites. Proteins on the infected red
blood cell which are mostly variant and with relatively
low immunogenicity can be targets of antibodies which
recruit the infected cells for phagocytosis. Proteins on
the merozoite actively participate in the successive coor-
dinated events that culminate in the erythrocyte invasion
[7]. Several merozoite surface proteins and others se-
creted by the apical organelles interact with erythrocyte
ligands. This interaction favors adhesion, apical reorien-
tation and creation of a moving junction that allows the
invagination of this parasite form into the erythrocyte,
leading to the formation of a parasitophorous vesicle
membrane (PVM) in which the parasite resides after in-
vasion (reviewed in [8]). Many of the merozoite antigens
act as targets of the natural antibody immune response
[9,10] and several of them have been implicated in the
development of clinical protection [11-17] and therefore
are present in the anti-blood stage vaccine formulations
which are currently being tested [18-21].
In the Brazilian Amazon, the transmission and inci-
dence of P. falciparum malaria is quite different from
Africa [22]. Many localities which experienced periods of
high malaria transmission in the past [23], presently
show low and seasonal P. falciparum transmission [24].
There is also a significant genetic structuring in parasites
from the Western Amazon suggesting a paucity of dif-
ferent circulating strains [25,26]. Coincidently, the reper-
toire of variant genes of P. falciparum is restricted and
redundant [27]. This special situation of exposure to
restricted numbers of antigens in addition to the obser-
vation of uncomplicated infections probably explains
previous data regarding a high incidence of asymptom-
atic carriers and/or persons to which the majority of
new infections are without symptoms [28]. Regardless of
the apparently functional immune protection of these
asymptomatic carriers, they do represent a persistent
source of P. falciparum infections [29] in Amazonian
settings.
On the basis of this epidemiologic background charac-
terized as a high incidence of asymptomatic infections
with the occurrence of sporadic symptomatic cases in the
same population in the Amazon, we set out to analyze
which parameter of the humoral immune response against
merozoite antigens is decisive for the observed outcome
during a P. falciparum malaria infection. To do this, we
focused on the recognition of a number of antigens in-
volved in the erythrocyte invasion process, namely pro-
teins of the MSP and EBL families and AMA1. In order to
test the response against relevant versions of target pro-
teins, we analyzed the circulating alleles of merozoite
genes from field isolates present in the blood of sympatric
symptomatic and asymptomatic carriers and produced
parts of them as recombinant antigens. Then, the humoral
immune response against these antigens was measured by
ELISA and correlated to disease outcome and epidemio-
logical parameters.
Methods
Study site
The study was conducted in a riverside area of Porto
Velho, the capital of Rondônia state, in the Western
Brazilian Amazon. Four localities on the riverbanks of the
Madeira River were chosen, Vila Candelaria, Bate-Estaca,
Santo Antonio and Engenho Velho. The first three are lo-
cated one after the other on the right bank of the Madeira
River and the last, on the left bank. As in other endemic
settings in Brazil, the majority of malaria cases in these
areas are caused by Plasmodium vivax [22] and the overall
endemicity for Malaria is relatively low. The annual distri-
bution of malaria cases in these areas paralleled the sea-
sonal rain distribution with a peak of incidence in the
beginning (October-November) and other after the peak
of rainy season (February-March) [24]. The principal
vector in Brazilian malaria endemic areas is Anopheles
darlingi [22].
Study design
During the low malaria transmission season (August-
September), a cross sectional study was conducted in
the four localities by the IPEPATRO field team and
FUNASA technicians. Children older than one year to
seniors, both male and female, were invited to partici-
pate and more than 50% of residents from each locality
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agreed to participate. After each participant (or the legal
guardian for children) signed a specific consent form, a
5 ml blood sample was collected by peripheral veni-
puncture, independent of the presence of malaria symp-
toms. Individuals with any malaria symptoms (fever
>37.8°C, prostration, headache, chills, tremors, myalgia,
nausea and vomiting) and P. falciparum positive thick
blood films were immediately treated after blood was
taken and were included in the symptomatic group. The
P. vivax symptomatic patients were immediately treated
and were not included in the study. The participants with-
out symptoms but positive by PCR for P. falciparum were
followed up for 1 month by a medical team to verify the
development of symptoms. When symptoms appeared, a
thick blood film was performed and individuals which
were positive for falciparum malaria were treated immedi-
ately and included in the symptomatic group. Persons
who did not develop symptoms even with P. falciparum
positive PCR were classified asymptomatic and treated
after the follow-up. Persons with positive PCR for P. vivax
without symptoms were treated immediately after the
parasite diagnosis and not included in the study. Only one
asymptomatic patient presented parasites in the thick
blood smear (routinely, 50 fields per blood smear were
monitored) while the remaining asymptomatic infections
were only diagnosed by PCR. Finally, 28 samples were ob-
tained from symptomatic patients (28 erythrocyte concen-
trates and 27 plasma samples) and 25 from asymptomatic
patients (25 erythrocyte concentrates and 24 plasma sam-
ples). In order to calculate reactivity indices, 13 plasma
samples from persons living in non-endemic regions of
Brazil and never exposed to malaria were included as the
negative control group.
Ethical statement
The study was approved by the Ethics Committee for
Research involving Humans at the Institute of Biomedical
Sciences of University of São Paulo (protocol 741/2006).
The patients were treated according to the guidelines for
treating malaria patients of Brazil’s Health Ministry,
available at the site (http://bvsms.saude.gov.br/bvs/publica-
coes/guia_pratico_malaria.pdf) based on WHO recom-
mendations (http://whqlibdoc.who.int/publications/2010/
9789241547925_eng.pdf).
Blood sampling
The blood samples were collected in sterile tubes with
EDTA, centrifuged (400 g, 5 minutes, room temperature)
and fractioned into plasma and packed erythrocytes. One
volume of glycerol was added to each plasma sample and
these samples were maintained at −80°C. 250 μl of the
packed erythrocytes were submitted to Plasmodium
genomic DNA (gDNA) purification by the Proteinase K/
phenol-chloroform method [30].
Identification of Plasmodium infection by PCR, locus
amplification
Each gDNA extracted was submitted to nested PCR in
order to verify the presence of the Plasmodium genus by
amplification of ssrRNA fragments as described previ-
ously [30]. According to the PlasmoDB database (v5.5),
primer pairs covering polymorphic regions and/or im-
mune epitopes of MSP4, MSP5, MSP6, MSP7, MSP9,
MSP10, AMA1, EBA140, EBA175 and EBA181 were de-
signed on the basis of the 3D7 genome sequences.
Primers described previously to amplify MSP1 block 2
[31], the polymorphic regions of MSP2 [32] and MSP3
[11] and the M2 domain of MAEBL [33] were used. A
BamHI or BglII restriction site was added at the 5′ ex-
tremity of each forward oligonucleotide. The sequences
of the primer pairs used as well as the amplified regions
are shown in Additional file 1: Table S2 and in
Additional file 2: Figure S2, respectively. Field isolate
gDNAs extracted from blood from symptomatic and
asymptomatic infections were submitted to 35 amplifica-
tion cycles of denaturation at 94°C (1 minute), annealing
at temperatures specific for each pair of primers (1 mi-
nute), polymerization at 72°C (1 minute) and a final
polymerization at 72°C for 10 minutes. Taq Polymerase
enzyme (Fermentas) was used according to the manufac-
turer’s instructions. In all reactions, 3D7 gDNA was used
as a positive control and an amplification solution with-
out gDNA as negative control.
Cloning and sequence analysis
All amplified fragments from each gDNA were A/T
cloned in pGEM-T easy vector (Promega) according to
the manufacturer’s instructions. Ligations were trans-
formed in E. coli DH10B cells. Five recombinant clones
were analyzed by automated DNA sequencing using the
BigDye 3.1 Terminator Cycle Sequencing kit (Applied
Biosystems) according to the manufacturer’s instructions
and sequencing was conducted in an ABI 3100 auto-
matic sequencer (Applied Biosystems). The identity of
each sequence was confirmed by BlastN analysis. All ob-
tained P. falciparum sequences of each merozoite gene
were loaded in Clustal X (1.83) and aligned. An identity
matrix was generated for each sequence group and se-
quences were clustered into groups with identities of
95% or more which were then considered identical. This
number was chosen based on the assumption that differ-
ences above this cutoff would most probably generate
proteins which are recognized similarly by antibodies
present in human sera. One representative sequence
from each group of >95% identical sequences was sub-
cloned via BamH1/EcoR1 digestion and ligated in pGEX2T
(Amersham Pharmacia). Data regarding the sequence
diversity of MSP1 block 2 [34] and MSP2 [35] were used
to define allelic groups and variants.
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Protein expression
Recombinant pGEX2T plasmids were transformed into
E. coli BL21 DE3 pLys Codon Plus RIL cells and grown
on a shaker at 37°C in 5 ml aliquots overnight in LB
supplemented with ampicillin (100 μg/μl) and chloram-
phenicol (34 μg/μl). 1 ml of the preinoculum was then
transferred into 100 ml LB supplemented with ampicillin
(100 μg/μl) and grown to optical densities (600 nm) of ≥
0,6 and induced by the addition of IPTG to a final con-
centration of 0,1 mM for 3 hours at 37°C on a shaker at
200 rpm. Bacterial cultures were then centrifuged for 20
minutes at 4°C and 2300 g in a Sorvall R7 benchtop cen-
trifuge. The bacterial pellet was dissolved in 5 ml PBS/
1% Triton X-100 (pH 7.4) and Lysozyme (0,1 mg/ml,
Sigma) was added. The solution was then incubated
rocking for 5 minutes at room temperature and frozen
for 2 hours or overnight at −20°C. Afterwards, the ma-
terial was thawed and submitted to five sonication cycles
(Branson sonifier, 30 seconds, force 40, on ice) interca-
lated by 30 seconds without sonication. 5 ml of PBS 1X/
1% Triton X-100 was added and centrifuged as described
above. Supernatants were then incubated with 100–
200 μl of Glutathione-sepharose resin (Amersham
Pharmacia) pre-washed with PBS (pH 7.4), under continu-
ous agitation at room temperature. After one hour, the
resin was washed once with PBS/1% Triton X-100 and
twice with PBS. Then, 500–750 μl of elution buffer (0,1 M
Tris–HCl pH 8, 0,12 M NaCl and 10 mM reduced glutha-
tione) were added to the resin in 1,5 ml micro tubes, and
incubated at RT under continuous agitation for 1 hour,
after which the supernatant was harvested by centrifuga-
tion for 1 minute, 12000 rpm. Recombinant proteins were
submitted to electrophoresis in SDS-PAGE under redu-
cing conditions. All expressed peptides were submitted to
Western Blotting analyses with anti-GST mouse serum to
test the correct size of the fusion protein (data not shown).
The concentration of recombinant proteins was calculated
by the Bradford method.
ELISA assays
Flat wells plates (medium binding) were coated overnight
at 4°C with 50 μl polypeptide solution (125 ng/well) in so-
dium carbonate buffer (50 mM, pH 9.6). After one wash
with PBS/0.05% Tween 20 (washing solution), 200 μl/well
of blocking solution (PBS, 0.05% Tween 20 and 4%
skimmed milk) was added for 2 hours at 37°C. Plates were
washed three times with washing solution and incubated
for one hour at 37°C using 1/200 diluted plasmas from
asymptomatic and symptomatic patients. This incubation
occurred in blocking solution with 1% skimmed milk
(incubation solution). All plasmas were tested in dupli-
cates in wells coated with fusion peptide and background
binding to the GST fusion was estimated by wells which
contained only rGST. After five washes, plates were
incubated with 1/1500 diluted goat anti-human IgG HRP
antibodies (KPL) in incubation solution for one hour at
37°C. After five washes, 50 μl/well of TMB substrate
(KPL) was added and 10 minutes later the reaction was
stopped with 50 μl/well of 1 M HCl. The OD450nm was
read in a spectrophotometer using the OD595nm value as
reference. Thirteen plasmas from persons without previ-
ous contact with Plasmodium sp. were used as negative
controls. IgG subclass-specific ELISA assays for each pep-
tide were performed as follows: Monoclonal mice anti-
bodies against each anti-human IgG subclass (anti-IgG1
(2C11, ab1927), anti-IgG2 (3C7, ab1935), anti-IgG3
(5G12, ab1928) e anti-IgG4 (5C7, ab1930) (Abcam, Inc.,
Cambridge, Massachusetts, USA) were added after the pri-
mary incubation, diluted 1/3000 in incubation solution.
Afterwards, goat anti-mouse IgG HRP antibodies (KPL)
were added, 1/2500 in incubation solution.
Statistical analyses
Microsoft Excel 2007 spreadsheets were used to collect
the raw data and perform OD cutoff calculations while
statistical analyses were run in SPSS (15.0). The quanti-
tative variables for the epidemiologic data were: age,
time living in an endemic malaria area (TLEA), time liv-
ing at the same actual address (TLSA), number of previ-
ous symptomatic falciparum malaria infections (NPMF),
time since the last symptomatic malaria falciparum in-
fection (TLMF), number of recombinant antigens recog-
nized in the ELISA assays (NRAR). These variables were
compared between symptomatic and asymptomatic
groups by Mann-Whitney’s U test for comparisons be-
tween two independent samples. p values lower than
0.05 were considered significant.
Instead of optical densities, we used reactivity indices
(RIs) to estimate the specific antibody reaction, thereby
eliminating signals from residual E. coli derived compo-
nents in the recombinant protein preparations. For this,
the optical density (OD) values from the negative plasma
control group were used to estimate the reaction cut-off
for each antigen tested. The average ODfinal (ODfinal =
ODantigen-ODGST) plus 2 SD (standard deviations) was
taken as the cutoff value. ODantigen is the optical density
that was measured using all plasmas on the GST-fused
antigen while ODGST is the optical density that was mea-
sured the same plasmas on GST-coated wells. The RI for
each reactive plasma and each antigen (OD > cutoff ) was
calculated by dividing the OD value by the cut-off reac-
tion value. The RIs from symptomatic and asymptomatic
plasmas for each tested antigen were compared by
Mann-Whitney’s U test for comparisons between two in-
dependent samples. For comparisons between different
alleles or variants, the RIs from each clinical group were
compared by Wilcoxon signed rank test for comparisons
between paired samples. p values lower than 0.05 were
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considered significant for the two tests. The OD values
obtained in IgG subclass ELISA assays were compared
between symptomatic and asymptomatic individuals by
Mann-Whitney’s U test.
Cross tab analysis was used to evaluate the frequency
of reactive plasmas for each antigen in groups of symp-
tomatic and asymptomatic patients. This analysis was
also applied to analyze the frequencies of different alleles
of polymorphic genes present in parasites collected from
these patient groups. The Chi-square (Χ2) method or,
whenever necessary, Fisher’s exact test identified the dif-
ferential frequencies (significant when p < 0.05).
Association between qualitative dichotomous variables
“symptoms” (Yes-symptomatic or No-asymptomatic) and
“antigen recognition” (Yes-recognized or No-not recog-
nized) was also verified by cross tab analysis. The strength
of association was calculated using the V Cramér coeffi-
cient that varies from 0 to 1 (0-no association to 1-strong
association). Odds ratio (OR) values were obtained from
tabs showing true association among variables, verified by
the X2 method (p < 0.05). OR values represent the ratio of
odds of non antigen-recognizing individuals to present an
asymptomatic profile in relation to antigen-recognizing
individuals. Values lower than 1 indicate that antigen-
recognizing individuals are more likely to remain free of
symptoms compared to individuals who do not react
against tested antigens. Association between the asymp-
tomatic profile and intensity of antigen recognition was
verified by logistic regression. The response variable
(symptoms) was categorized in 0 (yes = symptomatic) or 1
(no = asymptomatic) and the explanatory variables (RI
values) were categorized in terciles. Firstly, each explana-
tory variable was analyzed by a likelihood ratio test in the
univariate model to verify association or not with the re-
sponse variable. The association force was calculated using
the Wald test. The OR points to the ratio of odds (the
chances in relation to the non-chances) that each expla-
natory variable offers for the response variable assuming
the “1” value (asymptomatic profile). In the multivariate
model, we then verified which explanatory variables were
maintained independent in offering chances to present an
asymptomatic profile, and this was done by the partial
likelihood ratio test.
Results
Circulating P. falciparum strains in a Western Amazon site
show low variability in major merozoite surface antigens
The successful immune response against P. falciparum
malaria is believed to depend on the recognition of both
variant antigens on the infected red blood cell and also
merozoite antigens. In cases such as allelic forms of MSP1
polymorphic block 2 there is limited cross-recognition be-
tween proteins. In order to measure the immune response
against antigens which in fact occur in the circulating
parasite strains of the infections studied herein, we first
identified the sequences of the major antigens. As shown
in Additional file 1: Table S1, few different sequences per
target were found in the circulating isolates. Due to
smaller genomic DNA quantities the amplification success
was lower in samples from asymptomatic carriers and the
genes from some antigens were not amplified at all in
these samples (Additional file 1: Table S1). Importantly,
the PCR primer sequences were chosen from alignments
of deposited sequences of each gene, avoiding poly-
morphic regions at the priming sites (Additional file 2:
Figure S2). As expected, several different alleles were
discovered in the MSP1 polymorphic block 2 fragments in
a number of samples indicating polyclonal infections
(Additional file 1: Table S1). Most of the non-MSP1 se-
quences detected were very similar or identical to 3D7 se-
quences. When deviations from the 3D7 sequences were
found, they consisted of point mutations (MSP3 and
MAEBL) or variations in the number of repetitions (vari-
ants of MSP1 and MSP2 alleles and MSP10). We then
wanted to elucidate if the occurrence of certain genotypes
was associated with the observed infection type (symp-
tomatic versus asymptomatic). In the case of MSP1 block
2, we observed that the RO33-type sequence was the most
frequent allele, present in approximately 46% of all field
isolates from the four localities (26/56) (Figure 1). This al-
lele was more frequent (approximately 55%) among iso-
lates collected from symptomatic than asymptomatic
infections (X2DF=1 = 4.178, p < 0.03) (Figure 1). K1-type se-
quences were the most frequent alleles in samples from
asymptomatic carriers (44%, X2DF=1 = 6.676, p < 0.009) and
K1A, the most frequent variant among this allele family.
MAD20-type sequences were present in 24% of isolates
from asymptomatic and approximately 29% of isolates
from symptomatic infections. Among these, MAD20A
was the most frequent over the two clinical groups
(Figure 1). Five isolates from asymptomatic infections
presented polyclonal infections with two or three different
allele sequences. The same was verified in five isolates
from symptomatic infections (Additional file 1: Table S1).
IC1-type sequences of MSP2 were predominant over the
FC27 type in symptomatic infections, however, only one
MSP2 sequence was amplified from isolates present in
asymptomatic infections, making correlation analysis be-
tween infecting genotype and disease outcome impossible,
as was the case for the remaining targets (Figure 1 and
Additional file 1:Table S1).
Recognition frequency of recombinant merozoite
antigens
In the next step all sequences different at a 95% identity
level were expressed as soluble bacterial GST fusion pro-
teins (Additional file 2: Figure S2). In order to assure
that the conformation of the produced antigens at least
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partially reflected native antigens, we heat-inactivated a
number of the antigens including rMSP119 and rEBA175
which are known to possess conformational epitopes. As
a result, the recognition of MSP119 decreased to half for
the plasmas tested, while for EBA175 only a partial de-
crease was observed (Additional file 2: Figure S3). This
indicates that the produced antigens contained conform-
ational and linear epitopes that could be recognized by
infection-induced antibodies. Then, the presence of anti-
bodies in plasmas from symptomatic and asymptomatic
carriers was tested. Importantly, the decisive factor for
inclusion in the “symptomatic” group of individuals was
the occurrence of any of the typical malaria symptoms
(see Methods section) together with the detection of
parasites. On the other hand, the persistent absence of
any symptom and the presence of parasites defined the
“asymptomatic” individual.
We measured the recognition of all antigens by calculat-
ing their reactivity indices. This method eliminates the
background signal caused by the binding of antibodies
against traces of E. coli proteins which remained in the
preparation of the recombinant antigens. The produced
antigens were recognized at different intensities with RI
values ranging from 1 to 100 (Figure 2) and the most rec-
ognized protein was the C-terminal portion of MSP1,
followed by rMSP10, rEBA175 and rMSP3 (Figure 3). On
the other hand, other antigens such as rEBA181 and
rMAEBL were only recognized by a small fraction of the
plasmas. Importantly, all proteins were expressed in a bac-
terial expression system and the quality of folding is most
probably different between different proteins. This per-
mitted only the evaluation of reactions between different
plasmas but not any affirmation regarding the absolute IgG
quantity against any antigen tested herein or quantitative
p<0.03
p<0.009
A
B
Figure 1 Frequency of MSP1 block 2 alleles in Rondônia field isolates. A: RO33 was the most prevalent followed by the K1 allele. The RO33
allele was more prevalent in symptomatic infections while K1 alleles were dominant in asymptomatic samples (Chi-square method, p < 0.03 and
p < 0.009, respectively). B: K1A and MAD20A were the most frequent K1 and MAD20 type sequences for both groups. Note that the sum of
values is higher than 100% since a number of isolates presented more than one genotype at this locus.
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comparisons between different antigens. We then mea-
sured which of these antigens were recognized at a higher
frequency by plasmas from asymptomatic or symptomatic
patients. As shown in Figure 3, MSP1 block 2 allele
MAD20 was recognized by a higher number of symp-
tomatic patients than asymptomatic carriers (p = 0.0206,
Fisher’s exact test). There was no specific preference of
recognition of rMSP1 block 2 alleles by plasmas from indi-
viduals infected with a parasite genotype bearing a deter-
mined MSP1 block 2 allele (Additional file 2: Figure S4).
For example, persons infected with a MSP1 block2-
MAD20 type did not have more or less antibodies against
RO33 and K1 type alleles, and vice versa. rMSP119, a
component of several vaccine formulations, was rec-
ognized by equal numbers of individuals from both
groups. This was also the case for all other antigens
tested herein. Finally, MSP5 and MSP9 were recognized
by a higher portion of asymptomatic than symptomatic
individuals (MSP5: p = 0.0069) and MSP9: p = 0.0047,
Fisher’s exact test).
Antibody titers seem to inversely correlate with
symptoms
The antibody titer and specificity against antigens may
be important for lower parasite proliferation rates and
indirectly the disease outcome. We therefore evaluated if
Figure 2 Antibody recognition of recombinant antigens in symptomatic and asymptomatic patients. ELISA results computed to reactivity
indices are shown and the recognition strength is expressed in color codes. Columns show results for different recombinant proteins being
1-MSP1_RO33, 2-MSP1_MAD20, 3-MSP1_K1, 4-MSP119, 5-MSP2_FC27, 6-MSP2_IC1-69, 7-MSP2_IC1_I4 (3D7-like), 8-MSP3_3D7, 9-MSP3_I4, 10-MSP4,
11-MSP5, 12-MSP6, 13-MSP7, 14-MSP9, 15-MSP10_17, 16-MSP10_I3, 17-MSP10_3D7-like, 18-AMA1_A, 19-AMA1_B, 20-MAEBL_I4, 21-MAEBL_3D7-
like, 22-EBA140, 23-EBA175, 24-EBA181. The sequences used for expression are depicted in Additional file 2: Figure S1 and the accession numbers
are informed in Additional file 1: Table S1.
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the quantity of a given antibody was related to the asymp-
tomatic status. For this, we compared the obtained RI
values for both clinical groups with the observed disease
status at the time of blood withdrawal. Similar to previous
studies, very high titers of antibodies, seen as the highest
RIs, were observed against parts of the merozoite protein
1 antigens rMSP119 and the allelic forms of MSP1, poly-
morphic block 2. The protein rMSP3_3D7-like was largely
recognized by plasmas from both clinical groups and RI
values higher than 10 represented 50% of RI values in the
asymptomatic group whereas in the symptomatic group
these values represented 18.5% of the RI values. Four
plasmas in the asymptomatic group had RIs higher than
50 against rMSP3_3D7-like whereas only one presented
with this feature in the symptomatic group. Plasmas also
reacted strongly and equally against rMSP10_I3 and
rMSP10_3D7-like and showed RI > 10 in both symptom-
atic and asymptomatic infections. Only plasmas from
asymptomatic patients had RI values of more than 10 to
antigens rMSP2_FC27, rMSP2_IC1, rMSP4, rMSP9 and
rEB175, and some plasmas had an RI > 50 to rMSP9.
When tested for significant differences, plasmas from
asymptomatic patients had significantly higher RIs against
rMSP4 (U = 210.5, p < 0.030), rMSP5 (U = 212, p < 0.004),
rMSP9 (U = 189.5, p < 0.002) and rEBA175 (U = 197, p <
0.014), as tested by Mann-Whitney’s U test (Figure 4)
while other strongly recognized antigens showed no
statistically significant differences (Figure 5). Importantly,
rMSP5 was recognized by 42% of plasmas from the
asymptomatic group and the observed RI values were only
1 to 4.9.
Protection from clinical malaria or development of the
asymptomatic profile is independently associated with
the recognition of MSP5, MSP9 and EBA175
We performed two types of analyses to investigate the as-
sociation between the antibody response to a specific anti-
gen and the asymptomatic profile, working with the
variable RI as either a qualitative or a quantitative param-
eter. The crosstab analysis between the qualitative di
chotomous variables “symptoms” (Yes = symptomatic and
No = asymptomatic) and “antigen recognition” (quantita-
tive variable RI transformed in qualitative variable Yes =
recognized (RI > 1) or No = not recognized (RI ≤ 1)) pre-
dicted individuals were 8.9 or 8 times less likely to present
with symptoms if their plasma recognized rMSP5 (OR =
0.112, IC95% = 0.021-0.585) or MSP9 (OR = 0.125, IC95% =
0.030-0.529) respectively. Using logistic regression ana-
lysis, the intensity of the recognition of rMSP5 and
rEBA175 (higher RI values against these antigens pro-
duced by plasmas from asymptomatic individuals grouped
in the 3rd tercile) was independently associated with
the explanatory variable “clinical profile-symptomatic or
asymptomatic”. Higher antibody levels against rMSP5 and
rEBA175 resulted in an odds ratio of 9.4 (IC95% = 1.29-
69.25) and 5.7 (IC95% = 1.12-29.62, logistic regression),
respectively, to associate with the asymptomatic status
(Tables 1, 2 and 3). Notably, not all asymptomatic patients
had antibodies against these antigens, but they were re-
cognized more frequently and stronger by asymptomatic
individuals compared to symptomatic patients. We also
did not find a relevant association between these antigens
and any other epidemiological parameter described in
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Figure 3 Percentage of recognition of different proteins by plasmas from asymptomatic (“A”) and symptomatic patients (“S”) from the
same area. The tested antigens are shown on the x-axis while the percentages of plasmas with positive recognition (RI > 1) per clinical group are
shown on the y-axis. The reactivity index RI was calculated by dividing OD values from sample plasmas against given antigens by the a media
plus 2 standard deviations of OD values obtained with the same antigens recognized by 13 malaria-naïve subjects (see also Methods). Statistical
differences are indicated as asterisks and were found for the MAD20-type sequence of MSP1 block 2: S > A (p = 0.0206), MSP5: A > S (p = 0.0069)
and MSP9: A > S (p = 0.0047).
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Materials and Methods. This seems to point to the hy-
pothesis that the acquisition of protection to clinical mal-
aria probably involves the recognition of other relevant
antigens or the development of other important features
of the immune response, such as the regulation of the
pro-inflammatory immune response.
IgG Subclasses slightly differ in patients with or without
symptoms
Distinct IgG subclasses indicate the nature of the acquired
immune response, pointing to the differential participation
of components of cellular mediated immunity or inflam-
matory response regulation. In order to detect if the IgG
subclass distribution was altered between the two clinical
groups, plasmas that presented RIs > 10 against a given
antigen were used to determine the IgG subclasses involved
in the recognition of the respective antigen. In plasmas of
symptomatic and asymptomatic patients, we observed dif-
ferences in the IgG subclass profile in their response
against the RO33 type of MSP1 block 2 and rMSP119, but
no significant differences (although borderline) were seen
against rMSP3_3D7-like and rMSP4 (Figure 6). In both
groups, the predominant IgG subclasses reactive against
RO33 were IgG1 and IgG3. Plasmas from asymptomatic
patients presented with higher quantities of IgG3 than
plasmas from symptomatic patients (U = 11, p < 0.031) and
the same was true for IgG4 (U = 6, p < 0.005). All sub-
classes of antibody against rMSP119 were higher in plasmas
from symptomatic patients: IgG1 (U = 43, p < 0.000), IgG2
(U = 75.5, p < 0.003), IgG3 (U = 100, p < 0.033) and IgG4
(U = 89.5, p < 0.013), but IgG1 was predominant in both
groups. Plasmas from symptomatic infections presented
with a predominant response of IgG1 against rMSP3_3D7-
like while the predominant subclasses were IgG1 and IgG3
in asymptomatic infections. However, there was no dif-
ference in IgG1 among plasmas from both groups but a
tendency to a higher quantity of IgG3 in plasmas from
asymptomatic carriers (U = 25.5, p < 0.053). The predomin-
ant antibody subclasses to rMSP4 were also IgG1 and
IgG3, but no differences between plasmas from both
groups were observed. Nevertheless, a tendency towards
higher quantities of IgG3 in plasmas from the asymptom-
atic patients was noted (U = 7, p < 0.056). No subclass dif-
ferences were observed against the antigens rMSP7 and
rMSP10_3D7-like, in the plasmas for which titers were
measured. The predominant subclasses reactive against
rMSP7 were IgG1, IgG3 and IgG4 while IgG1 and IgG3
were increased against rMSP10_3D7-like. All plasmas
used to determine the subclasses reactive against antigens
rMSP2, rMSP9 and rEBA175 belonged to the asymptom-
atic group, since only these presented RIs higher than 10.
The predominant IgG subclass against MSP2 was IgG3
(Wilcoxon signed rank test, p < 0.018), while IgG1 was
found against rMSP9 (Wilcoxon signed rank test, p <
0.033). No differences in the IgG subclasses were found
against rEBA175 (Figure 6).
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Figure 4 Significant differences in the recognition of four merozoite antigens by antibodies from asymptomatic individuals. The
distribution of RI values of plasmas recognizing rMSP4 (A), rMSP5 (B), rMSP9 (C) and rEBA175 (D) among clinical groups (27-Symptomatic (S)
and 24-Asymptomatic (A)) is shown. All differences were statically significant (p < 0.05) by Mann-Whitney’s U test.
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The duration of the humoral response, seen as the
maintenance of antibody titers against target proteins, is at
least partly expected to be important for the control of
parasitemias. In order to address the longevity of the
IgG response against determined targets, a subgroup of 10
asymptomatic and 3 symptomatic patients had their blood
samples collected at 30 and 60 days after the first blood
retrieval and treatment (these follow-up data are not
included in Table 1). Due to the small number of plasmas,
these were analyzed together. While the antibody quantities
A B
C D
E
IC69_rMSP2rMSP1_RO33
rMSP119 rMSP3_3D7
rAMA1_B
re
a
ct
iv
ity
 in
di
ce
s
Figure 5 Relevant vaccine related antigens are not significantly stronger recognized by antibodies from symptomatic or asymptomatic
individuals. Results for the distribution of RI values using plasmas from both clinical groups as in Figure 4 is shown for rMSP1_RO33, rMSP2_IC-69,
rMSP119, rMSP3_3D7 and AMA1_B (graphs A to E, respectively).
Table 1 Variables associated with the history of exposure to malaria parasites in general and to P. falciparum
Variables Number of
individuals
(A/S)
Range Median in
whole sample
25%-75%
percentiles whole
sample
Median
from A
group
25%-75%
percentiles from A
group
Median
from S
group
25%-75%
percentiles from S
group
Age (y) 51 (24/27) 4-84 24 15-40.5 28 16-53 22 13-34
TLEA (y) 51 (24/27) 4-83 22.5 14-40.5 27 15-53 21 13-33
TLSA (y) 51 (24/27) 0-60 10 4.75-23.25 10 4-28 9 5-20
NPEF 47 (23/24) 0-30 4 2-5 4 1-8 3 2-5
NAR 51 (24/27) 0-26 13 7-16 14 6-18 13 7-14
TLSE (y) 48 (24/24) 0-30 1 1-3.5 2 1-14 1 1-1
Shown are the parameters symptomatic (S), asymptomatic (A), year (y), time of living in endemic area (TLEA), time of living in the same address (TLSA), number of
previous episodes of falciparum infection (NPEF), number of recombinant antigens recognized (NAR) and time since the last symptomatic episode (TLSE). Note
that some information could not be obtained from the participants leading to varying values in column 2.
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measured as reactivity indices against rMSP1 block 2
(RO33) and rMSP3_3D7-like decreased over time, the
antibody levels against rMSP1 block 2 (MAD20 and K1)
and rMSP2_FC27 did not change between T0 and T30,
but decreased at T60. Antibodies against rMSP2_IC1-69,
rMSP2_IC1-I4, rMSP6 and rMSP7 increased by T30 and
then decreased by T60. No significant fluctuation of anti-
body levels was found against the remaining antigens
(Table 4 and Additional file 2: Figure S5). These results
underscore that the boosting of antibodies and the induc-
tion of memory is different from antigen to antigen.
Discussion
Immunity to blood stage malaria is seen as a process that
takes several years of continued exposure to infection and
reasons for this delay to a protective response may lie in
the suppression of an effective T cell response [36,37] and
the great diversity of antigens exposed to the host immune
system. There is striking evidence that the immune re-
sponse mediated by antibodies against either the infected
red blood cell surface or the merozoite is of prime import-
ance in the observed partial protection of individuals [38].
It appears that at least two types of a humoral response
against blood stage malaria may lead to clinical protection.
On one hand, the vaccine-induced production of function-
inhibiting antibodies against otherwise rarely recognized
antigens, such as the PfRh5 antigen [39], may lead to pro-
tection. On the other hand, a significant degree of protec-
tion mediated by antibodies is induced through years of
exposure to natural infection with multiple parasite lines
and antigens. In our study we tried to elucidate which anti-
gen or combination of antigens was recognized in order
to provide partial protection (asymptomatic status). In
contrast to the high throughput assay performed by
Crompton and colleagues [40], we analyzed antigens which
are expected to contribute to immunity since they are ex-
posed on the merozoite’s surface.
In the studied population, the individuals who suffered
from symptomatic infections showed almost identical epi-
demiologic features when compared to the asymptomatic
individuals. The variable TSLE (time since the last falcip-
arum symptomatic episode, Tables 1, 2 and 3) pointed to
the magnitude of the clinical immunity developed by
asymptomatic patients. A significant number of individuals
were not only asymptomatic at the onset of the study but
indeed had been symptom-free for up to 30 years regard-
less of continued exposure to the parasite. The symptom-
atic group consisted of individuals with relatively mild
malaria symptoms and low parasitemias and no single case
of truly severe malaria was observed in the area. Severe
malaria itself is a rare event in the Brazilian Amazon and
the reasons for this may be rapid access to adequate indi-
vidual antimalarial treatment, restricted virulence antigen
repertoires in circulating strains [27], low transmission
rates with Anopheles darlingi [24,41] being the principal
vector, and partly due to successful efforts to control mal-
aria in the Amazon region during the last 20 years [22].
Given the similar history of exposure to P. falciparum in
the herein tested symptomatic and asymptomatic patients
groups, it can be assumed that the former group is in the
process of acquiring clinical immunity to malaria and will
ultimately become part of the asymptomatics group. The
difference between the clinical status of each group lies in
the step at which their members are at in the process to
clinical immunity. Importantly, the sample number of 51
in our experiments is low compared to studies in other
endemic settings such as found in Africa or South East
Asia. Therefore, it would be important to confirm our
results in future studies using larger sample sizes. How-
ever, in the current situation of low transmission and
decreasing incidence of Plasmodium falciparum, it is
Table 2 Antigens correlated to a lower risk for symptoms
Antigens X2/(p) V de Cramér/(p) Odds ratio CI 95% para OR
MSP5 8.288 (0.004) 0.403 (0.004) 0.112 0.021–0.585
MSP9 9.256 (0.002) 0.426 (0.002) 0.125 0.030–0.529
See Methods section for calculation of values. CI is confidence interval and OR, odds ratio.
Table 3 Adjusted effects of categorized variables which predict a lower risk for symptoms in a multivariate model
Variables Log rank test Odds ratio Confidence interval 95% for OR
RI EBA175 X2 (2) = 14.660
3° Tercile x 1° Tercile p < 0.001 8.000 1.686–37.951
RI EBA175
X2 (2) = 20,775 p < 0.000
5.757 1.119–29.627
3° Tercile x 1° Tercile
RI MSP5 9.447 1.289–69.256
3° Tercile x 2° Tercile
A significant result indicates that strong responders against the indicated antigens are more likely to remain symptom-free. The terciles inform which ranked
groups of responses were compared. See the Methods section for calculation of values.
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logistically difficult to achieve this in most areas of the
Amazon.
When amplifying merozoite-protein related genes,
many negative results in the amplification step were
obtained and these occurred mostly in samples from
asymptomatic infections. There are two main possibilities
which may account for this observation: Firstly, the low
parasitemia in asymptomatic infections and consequently
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p
Figure 6 IgG subclass distribution against strongly recognized recombinant antigens (RI > 10). p values were calculated using Mann-Whitney's
(U) test. A: IgG1 and IgG3 subclasses were predominant with differences among groups reactive to rRO33 (IgG3 asymptomatic (A) > IgG3 symptomatic
(S)). The same was observed against rMSP4 with IgG1(A) > IgG1(S). IgG4 was present in reactive asymptomatic plasmas to rRO33 and in
reactive symptomatic plasmas to rMSP119. B: rMSP119(IgG1(S) > IgG1(A), IgG3(S) > IgG3(A)). C: Against rMSP3-3D7-like, both groups presented IgG1
and a tendency to IgG3(A) > IgG3(S). D: A tendency to higher IgG1 in plasmas from asymptomatics was observed against rMSP4. E/F: No differences
among groups to rMSP7 and rMSP10_3D7-like. IgG1, IgG3 and IgG4 were detected in symptomatic plasmas and IgG1 and IgG4 in asymptomatic
plasmas with no differences among IgG subclasses for both groups. G-I: Only asymptomatic plasmas presented RI > 10 to rMSP2_IC1-69, rMSP9 and
rEBA175. IgG3 were predominant in reactive asymptomatic plasmas to rMSP2_IC1-69 by Wilcoxon signed rank test and IgG1 were predominant in
reactive asymptomatic plasmas to rMSP9, by Friedman’s test. No difference was observed between IgG1 and IgG3 against rEBA175 in reactive plasmas
from asymptomatics.
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the small quantity of recovered plasmodial genomic DNA
may have been insufficient to permit the amplification of
determined genes. Secondly, it is possible that distinct
polymorphic sequences - different from the 3D7 genome –
were present at the primer binding sites in isolates espe-
cially from asymptomatic infections. However, even when
analyzing the alleles of the highly polymorphic block 2 of
MSP1, the quantity of different sequences found were
much smaller than previously described in high transmis-
sion malaria areas in Africa [34], but comparable to previ-
ous studies in the Amazon [42]. The rather small number
of different sequence types in the circulating field isolates
supports previously published data regarding the diversity
of the repertoire of var variant gene DBL-α sequences in
circulating isolates from the same area [27].
In P. falciparum donor samples from the same area, a
differentiation of parasite haplotypes associated to asymp-
tomatic or symptomatic donors was observed [43]. When
we clustered the obtained sequences for each analyzed
gene according to the criterion “symptomatic” or “asymp-
tomatic”, we detected a significant accumulation of iso-
lates with MSP1, block 2 sequence type K1 in parasites
from asymptomatic patients while symptomatic patients
showed a higher proportion of parasites with the RO33
type sequence. The reason for this is unclear and, to our
knowledge, has never been described in other reports. All
other sequences from antigens included in the study
showed high similarity to sequences from the 3D7 gen-
ome, reinforcing a limited diversity of relevant protein se-
quences in the Amazon.
We then asked if there were antigens (or groups of an-
tigens) which were recognized differentially by asymp-
tomatic or symptomatic carriers. One has to take into
account that the response in symptomatic patients may
reveal higher antibody titers against certain antigens.
This may lead to the probably erroneous interpretation
that the presence of antibodies is detrimental for the
health condition of the respective carrier. Also, the qual-
ity of antigens used may not permit exact conclusions
about the functionality of the detected antibodies. Many
of the antigens contain conformational epitopes in their
native full-length form and these were probably not
reproduced in our recombinant antigens, likely restrict-
ing the assay to the detection of antibodies against linear
epitopes. At least rMSP119 and perhaps rEBA175, how-
ever, contained conformational epitopes which could be
recognized by antibodies. This was seen by the heat-
mediated denaturation of these proteins leading to a de-
crease in their recognition (Additional file 2: Figure S3).
Testing of the leading erythrocyte stage vaccine candi-
dates MSP119, MSP2, MSP3 and AMA1 [20] has re-
vealed interesting features in the development of clinical
immunity to falciparum malaria in these low endemic
areas. The first falciparum episodes normally are suffi-
cient to generate IgG antibodies to MSP119. Intriguingly,
some asymptomatic patients exhibited no antibodies to
this antigen suggesting that antibodies against solely this
domain are not critical for an asymptomatic outcome,
regardless of its importance in the invasion process and
parasite survival [44]. Nevertheless, this antigen was
largely recognized in almost all patients in both groups
and the antibody response was maintained over time.
The IC1 allele of MSP2 was largely recognized in both
groups and the same was true for the rarely occurring
FC27 allele, although to a lesser extent but still at a
higher rate than may be expected from the genotyping
of circulating strains. The presence of antiMSP2_FC27
either corroborates the presence of shared epitopes be-
tween polymorphic sequences or a previous, more abun-
dant presence of the FC27 allele. A similar result was
observed in the study by Jordan and colleagues regarding
the occurrence of antibodies against determined allelic
forms of MSP3 [45] and this seems to be a feature for
areas with low transmission conditions such as those
found in the Western Amazon. It is known that MSP1
and MSP6 genotypes fluctuate in the Amazon area over
Table 4 Different antigens elicit differently enduring IgG
responses
rAntigens p < (T0 > T30) p < (T30 > T60)
MSP1bl2_RO33 0.028 0.015
MSP3_3D7-like 0.022 0.033
p < (T0 < T30) p < (T30 > T60)
MSP1bl2_MAD20 NS 0.028
MSP1bl2_K1 NS 0.043
MSP2_FC27 NS 0.018
MSP7 0.05 0.025
p < (T0 < T30) p < (T30 > T60)
MSP2_IC1-69 0.043 NS
MSP2_IC1-I4 0.026 NS
MSP6 0.011 NS
p < (T0 > T30) p < (T30 > T60)
MSP119 NS NS
MSP4 NS NS
MSP5 NS NS
MSP9 NS NS
MSP10 (3 alleles) NS NS
AMA1(2 peptides) NS NS
EBA140 NS NS
EBA175 NS NS
EBA181 NS NS
The significance of differences in the longevity of the humoral response in 13
serial samples (at 0, 30 and 60 days) is shown. For example, T0 > T30 means
that the average of RI values decreased at time point 30. NS means statistically
not different (Wilcoxon signed rank test). See also Additional file 2: Figure S5
for reactivity indices at time points 0, 30 and 60.
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time [42,46] and this is probably true for MSP2 geno-
types. No differences regarding the intensity of the im-
mune response of both clinical groups were observed,
despite the higher RI values to MSP2 antigens found in
the asymptomatic group. To our knowledge, no study
aiming to associate the anti-MSP2 response and protec-
tion has previously been done in the Amazon. In a study
analyzing immune responses and protection from clin-
ical malaria in the Gambia, a combined higher immune
response against MSP2 alleles and AMA1 was associated
to protection [47]. Polley and colleagues also found a
strong correlation between antibodies to MSP2 and pro-
tection [48]. IgG3 was the predominant subclass for IC1
and also for rMSP119 among asymptomatic plasmas and
may be associated to the asymptomatic profile, interact-
ing with phagocytes and favoring ADCC mechanisms,
such as the respiratory burst by neutrophils [49]. This is in
concordance with the data from other groups in settings
of higher endemicity (e.g. [50] and papers cited therein).
The polypeptide MSP3_3D7-like, the major MSP3 al-
lele found among the Rondonian isolates, was broadly
recognized by plasmas from asymptomatic and symp-
tomatic patients, however, with no differences that were
statistically significant. In a recent study monitoring in-
digenous populations from the Venezuelan Amazon,
smaller numbers of individuals with antibodies against
MSP3 (11.2%) compared to our study (70%) were found,
which is possibly due the fact that the study groups in
that work contained only a few parasite carriers [51].
Another study in the Peruvian Amazon also detected a
predominance of one distinct MSP3 genotype and a
similar recognition frequency of the MSP3 HB3 allelic
form (very similar to the 3D7 sequence) as found herein
[45]. In that study, the responses to the N-terminal and
the conserved C-terminal region were measured separ-
ately and the authors detected a higher recognition of
the polymorphic N-terminal portion of MSP3 compared
to the C-terminus. Our study used a peptide including
the variant N- and the conserved C-terminal region of
the MSP3_3D7 antigen, making us unable to dissect the
response either against the polymorphic N or the con-
served C-terminus as done in the study of Jordan and
colleagues. Notably, the same group also observed the
occurrence of MSP3 genotypes similar to those found in
our study [52].
The interaction of antiMSP3 specific immunoglobulins
with phagocytes and their role in ADCI mechanisms has
been described previously [53] and the higher portion of
IgG3 in asymptomatic individuals compared to symptom-
atic persons may underscore their importance in disease
outcome. However, the antibody response to this import-
ant vaccine candidate seemed short-lived as shown by a
fast decrease of the response in plasmas collected 30 or
60 days after the treatment. Perhaps for this reason, the
IgG3 subclass in some asymptomatic plasma became pre-
dominant. These residual anti-MSP3 IgG3 antibodies may
contribute to the maintenance of the asymptomatic pro-
file, pointing to its importance in the acquisition of clinical
immunity. In a study conducted in Senegal, the presence
of IgG3 was significantly associated with protection [11].
Importantly, a MSP3 based vaccine proved efficient in a
phase 1b vaccine trial [21].
The longer AMA1 peptide (rAMA1_B =M1 and M2
domains) showed a higher frequency of recognition than
the shorter (rAMA1_A) corresponding to the M1 domain
and the region between M1 and M2 domains. Analysis of
AMA1 recognition by plasmas from Papua New Guinea
showed that immune epitopes present in the M2 and M3
domains depend on the conformational structure of the
protein for antibody interaction. The cysteine-rich M1
and M2 domains and their loop structures [54] contain
conformational epitopes and are generally not well recon-
stituted in a prokaryotic expression system. The relatively
weak recognition of the two peptides expressed (IR < 5 for
AMA1_A and IR < 10 for AMA1_B) could be a conse-
quence of the probable linear structure of the recombinant
peptides used in our trials. When monitoring antibody ti-
ters in subsequent samples after treatment, no difference
in recognition by plasmas from asymptomatic and symp-
tomatic individuals was observed. Interestingly, the num-
ber of reactive plasmas among those collected 30 and
60 days after treatment increased over time. It is known
that there is an extensive polymorphism in the AMA1
peptide which is critical for immune escape [55]. Of note,
the expressed peptides also contain this region but in our
isolates there was only one AMA1-allele in circulation, in
contrast to what was found in other endemic regions [56].
Another tested antigen that probably suffers from incor-
rect folding during prokaryotic expression is MAEBL. Al-
though we found only two different sequences, we noticed
that these showed several amino acid changes present in
their M1 and M2 domains.
The immune response developed to MSP1 block 2 has
been associated with protection by some groups [57,58],
but not by others [34,59,60]. Aotus and Saimiri monkeys
immunized with native or recombinant MSP1 were pro-
tected when challenged with homologous or heterologous
P. falciparum strains [57,61]. These results indicated that
the C-terminal as well as the N-terminal regions of MSP1
can be associated to protection. This also raises the possi-
bility of immune crossreaction among the allele families.
Here, among the 24 recombinant peptides tested in ELISA
assays, the RO33 type-sequence of MSP1 block 2 gener-
ated the highest RI values (RI > 100), but these were not
restricted to one clinical group. Regardless of the decrease
in RI values observed in plasmas from asymptomatic pa-
tients collected 30 and 60 days after treatment, the sub-
classes identified in plasmas collected before treatment
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showed a predominance of cytophilic antibodies IgG1 and
IgG3 in both clinical groups, but asymptomatics exhibited
higher IgG3 quantities than symptomatics. Again, it is
possible that better protection is due to the interaction of
IgG3 and Fc receptors on the phagocytes’ surface, trigger-
ing mechanisms of ADCI described previously for this
antigen [62]. Interestingly, an IgG4 response was observed
against the RO33 type-sequence of MSP1 block 2, and this
was stronger in asymptomatic than in symptomatic pa-
tients and extended to MSP6 and MSP7 which form a
complex together with MSP1. When measured, the anti-
body response to MSP7 decreased over time, but in the
plasmas collected before treatment, IgG1 and IgG4 were
the predominant antigens with no differences among the
clinical groups. Few studies have addressed the humoral
response against MSP6 and 7 in populations, and none
have been done in Brazil. The recognition frequency of
MSP6 and 7 seen in our study group was significantly
lower than in malaria patients tested in India [63], perhaps
due to different exposure of patients or conformational
issues of the proteins used. In a recent study from the
Peruvian Amazon, a comparable recognition of MSP6 (C-
terminal fragment as used herein) was found [64]. MSP6
is found in two allelic forms in P. falciparum, and we
found a predominance of the 3D7 sequence, in accordance
with results by Neal and colleagues who analyzed isolates
from the Iquitos region [46].
The only antigens for which the intensity of the anti-
body response revealed differences in the recognition be-
tween symptomatic and asymptomatic plasmas were
rMSP4, rMSP5, rMSP9 and rEBA175. The first two have
a conserved sequence among different strains of P.
falciparum but unknown functions [65]. The acid-basic
repeat antigen (ABRA or MSP9) has been linked to the
proteolytic processing of band 3 protein [66], the puta-
tive erythrocyte receptor for MSP119 [67]. EBA175 is the
most important antigen implicated in the invasion of
erythrocyte by the sialic acid dependent invasion path-
way [68]. rMSP4 and rEBA175 were widely recognized
by plasmas from both clinical groups but revealed a
stronger response in plasmas from asymptomatic pa-
tients. Although rMSP5 was readily amplified in para-
sites from asymptomatic and symptomatic infections,
the antibody response was restricted to the asymptom-
atic group. Independently from the low RI observed in
the ELISA assays using rMSP5, the presence of anti-
bodies to this antigen and its intensity of recognition
predicted significantly higher chances for the absence of
symptoms and the development of the asymptomatic
profile, respectively. Notably, MSP5 is not essential for
parasite survival in vitro [69]. The antibody response
against MSP4 and MSP5 has never previously been
tested in Amazonian settings, and the overall recognition
of MSP5 was comparable to a recent study done in
Papua New Guinea (PNG), although we found much less
recognition in symptomatic individuals compared to the
study in PNG [70]. Perhaps for this reason, that study
also did not reveal a differential intensity of recognition
between asymptomatic and symptomatic individuals. A
result similar to what was found for rMSP5 was ob-
served for rEBA175 while the magnitude of antibody re-
sponse to rMSP9 only predicted higher chances for the
absence of symptoms. High levels of antibodies against
EBA175 were also shown to be protective against symp-
tomatic malaria in children in PNG [71], while no com-
parable study has previously been done in the Amazon.
Also, and to our best knowledge, no study has been con-
ducted which measured PfMSP9-specific antibodies in
natural infections. The correlation between the antibody
response against it and the asymptomatic status surely
makes this molecule an interesting target.
Our analysis revealed that the main potential vaccine
antigens MSP119, MSP2, MSP3 and AMA-1 were recog-
nized equally in number and intensity by both groups of
patients. Despite all concerns regarding the quality of
the expressed antigens and/or the restricted antigen rep-
ertoire in the Brazilian Amazon, it appears that the rec-
ognition of some of these antigens is dispensable for the
development of an asymptomatic profile or is another
indication that we are observing very similar groups in
relation to the clinical immunity to falciparum malaria.
On the other hand, what is the real importance of devel-
oping antibodies against MSP4, MSP5, MSP9 and EBA-
175, which were the only antigens tested in our study
recognized more by asymptomatic patients? Is the rec-
ognition of only one single antigen as effective as the
recognition of all four antigens?
To answer these questions, we performed the cross
tab and the logistic regression analysis. The multivariate
model was employed in the logistic regression to meas-
ure the independent contribution of each antigen to the
asymptomatic profile and this was achieved by the esti-
mation of the odds for this outcome. The only antigens
independently associated with the asymptomatic profile
were MSP5, MSP9 and EBA-175. This means that the
presence of antibodies against each of them is necessary
to generate or maintain the asymptomatic profile. Due
to this, a potential vaccine based on single merozoite
antigen would not likely induce the desirable protective
status, while a vaccine based on multiple merozoite anti-
gens may be better. Accordingly, the multiple target ap-
proach proved more effective in in vitro approaches to
measure the quality of vaccines (e.g. [72]). Considering
that the several existent parasite invasion routes are re-
dundant, the development of the asymptomatic condi-
tion will require the recognition of multiple antigens
involved in each of these routes. Two antigens, impli-
cated in two different invasion routes (MSP9 and EBA-
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175) were independently classified as important for the
development of the asymptomatic status, while the third
protein, MSP5, has still no assigned function and is also
non-essential [69]. It is important to note that the uni-
variate model of logistic regression defined odds ratios
associated MSP3_3D7 and MSP4 to the asymptomatic
status (data not shown). However, the multivariate model
which permits the visualization of the independent vari-
ables for a specific outcome did not confirm this result.
Further tests, perhaps with higher sample numbers, are
necessary to elucidate this issue especially when consider-
ing that MSP3 is a vaccine candidate already used in clin-
ical field trials [21].
Conclusions
The central question in the discovery of relevant vaccine
targets is how one can differentiate a protective antibody
response from a response generated through the on-
going exposure but which is still unable to provide clin-
ical protection. When divided into the two clinical
groups representing immune (asymptomatic – “pro-
tected”) and semi-immune (symptomatic – “suscep-
tible”) persons almost no differences among the
exposure variables to P. falciparum parasites were noted
and also an absence of differences in the immune re-
sponse generated to the majority of merozoite antigens
was observed. Of these, some are known to be involved
in the erythrocyte invasion such as MSP1, AMA1 and
EBA-175, while the others are probably involved directly
or indirectly in the same process. Our results point to
the hypothesis that the acquisition of clinical immunity
based on the humoral response is probably a cumulative
step- by-step process of expansion and refinement of an
antibody repertoire that reacts to a certain number of
merozoite antigens. One of the first recognized antigens
is apparently MSP119 because of the ample reaction of
plasmas from both clinical groups. The maintenance of
an antibody response to the majority of merozoite anti-
gens indicates the development and expansion of spe-
cific long-lived plasma cells in this cumulative immune
response [73]. The maintenance of exposure to falcip-
arum parasites then seems to enable the recognition of
other ligands important for invasion, such as EBA175, to
which an intense antibody response was restricted to
the asymptomatic group. Probably, the development of
clinical immunity requires the recognition of a greater
number of antigens that exert the same function in re-
dundant invasion pathways. Additionally, the recognition
of antigens that interact with important antigens that
are involved in the invasion process, such as MSP9, may
be important. The antibody response to the other poly-
morphic antigens was similar among the two clinical
groups, with no differences in the frequency or intensity
of the humoral immune response. In regard to the
conserved antigens MSP4 and MSP5, asymptomatic
plasmas exhibited differential recognition patterns and
antibodies to MSP5 were associated with protection from
clinical symptoms and the development of the asymptom-
atic profile. While MSP4 is considered essential to parasite
survival, MSP5 is not [69]. Our data seem to indicate that
merozoite antigens may predominantly induce cytophilic
antibodies that then probably interact with PMBC, trigger-
ing ADCI mechanisms. In accordance to what was shown
by previous studies, the development of an antibody re-
sponse associated to protection requires the recognition of
multiple antigens that act in redundant invasion pathways.
The antibody response to essential conserved antigens, not
under immune pressure, is perhaps the last step for the de-
velopment of a protective antibody immune response.
Additional files
Additional file 1: Table S1. Genotype diversity of amplified fragments
of merozoite genes (columns) per Pf field isolates (lines) in dashed (1 =MSP1
block 2) and color codes (other genes). White color = unsuccessful
amplifications and black color = 3D7-type sequences. 1 to 10 =MSP1 block 2
to MSP10, 11A = AMA1_A, 11B = AMA1_B, 12 =MAEBL, 13 = EBA140,
14 = EBA175 and 15 = EBA181. I1, I2, I3, I4 = isolates previously collected in
the same settings. AFI = Africa Field Isolate (Gabon). The dominant sequence
of each protein was used for expression and the sequences of the used
sequences can be found under the following GenBank accessions: RO33-
JX315617, MAD20A-JX412318, MAD20B-JX412319, MAD20C-JX412320,
MAD20D-JX412321, MAD20FCR3-JX412322, K1A-JX416338, K1B-JX416339,
K1C-JX416340, K1AFI-JX416341, MSP2FC27-JX424324, MSP2_IC1-69-JX424323,
MSP2_IC1_I4(3D7-like)-JX469122, MSP3K1-like-JX469137, MSP4-JX469123,
MSP5-JX469124, MSP6-JX469125, MSP7-JX469126, MSP9-JX469127,
MSP10_17-JX469128, MSP10_I3-JX469129, MSP10_3D7-like-JX469130, AMA1-
JX469131, EBA140-JX469132, EBA175-JX469133, EBA181-JX469134, MAEBL_I4-
JX469135, MAEBL_3D7-like-JX469136. The different MSP1 block 2 types are
shown below. Repeat motifs in K1 and MAD20 sequences and the RO33
peptide sequence from P. falciparum field isolate gDNAs. The references
where the sequences were found previously are indicated in the right
column. Table S2. Primer pairs to amplify specific fragments of merozoite
expressed genes. The properties of the recombinant peptides are shown:
C, conserved; P, polymorphic; ND - no specific property described for the full
length protein. Inserted restriction sites are shown in bold letters. F, forward
and R, reverse primer.
Additional file 2: Figure S1. Primer localization and amplified
sequences in coding regions of genes encoding tested antigens. Gene
models were extracted from PlasmoDB.org v5.5. Figure S2. Coomassie
stained, denaturing 8% SDS-PAGE of GST-fused proteins used in ELISAs:
A: 1: GST, 2–4, MSP1 block 2 alleles RO33, MAD20 and K1, 5–7: MSP2
alleles FC27, IC1_69, IC1_3D7like, 8–9 MSP3 alleles K1 and 3D7, 10: MSP4,
11: MSP5, 12: MSP6, 13, MSP7, 14: MSP8 (not tested in ELISAs), 15: MSP9.
B: 1: GST, 2–4: MSP10, 17, 369 and 3D7, respectively, 5: AMA1_A 6:
AMA1_B, 7: EBA140, 8: EBA175, 9: EBA181, 10–11: MAEBL type I4 and 3D7.
Figure S3. Recombinant GST-fused antigens partially possess conform-
ational epitopes which are destroyed upon heat denaturation. ELISAs
were performed as before using the indicated antigens either heated for
5 min at 95°C or not. The upper graph shows the percentage of recogni-
tion of heated antigens from four strongly and two weakly reacting
plasmas from asymptomatic individuals (corresponding to plasmas in
lanes 4, 5, 6, 11, 12, 13 in Table 1). The lower graph shows the OD450nm
values for unheated antigens. Figure S4. Reactivity of plasmas from
infections with determined MSP1-block2 alleles against antigen variants.
No statistical difference was observed in the response of plasmas from
carriers of the given MSP1 block 2 genotypes and their reaction against
MSP1 block 2 antigens. See Additional file 1: Table S1 for details of the
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genotypes. Figure S5. Reactivity indices (y-axis) of sera against antigens
in the follow-up analysis (day 0, 30 and 60), shown are median values
(horizontal line), 25-75% percentiles (boxes) with their deviations and
outliers (asterisks). Only values of antigens which were recognized
statistically different between at least two time points are shown
(see Table 4 for details).
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